Teprotumumab shows promise in small chinese thyroid eye study
NCT ID NCT07085117
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study looked at how well teprotumumab (TEPEZZA) works in real-world use for 5 Chinese patients with thyroid eye disease. The main goal was to see how many patients had a reduction in eye bulging (proptosis) after their last IV infusion. The study also collected basic information about the patients and their health at the start of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
teprotumumab (TEPEZZA)
What this could lead to
If successful, this could confirm that teprotumumab works in Chinese patients with thyroid eye disease, supporting its use in broader populations.
What could go wrong
This is a very small study (only 5 patients) and retrospective, so results may not apply to everyone. No new safety data beyond what is already known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boao Vanguard Hospital
Qionghai, Hainan, 571400, China